Sirtex Medical has announced a collaboration with Magle Chemoswed, a Sweden-based contract development and manufacturing organisation.
The development and commercial agreement grants Sirtex global use of Magle Chemoswed’s technology to develop a novel imaging agent for use in interventional oncology. Sirtex will have the exclusive license and commercialisation rights in the defined field of use. Magle Chemoswed maintains rights to its technology platform and to exclusively manufacture the product for supply to Sirtex. The development programme will begin in the third financial quarter of 2020.
“Our partnership with Magle Chemoswed marks an important step in our company growth, portfolio expansion, and investment in patient-centered care worldwide,” says Kevin R Smith, Chief Executive Officer (CEO) of Sirtex. “We are honoured to utilise this technology platform to advance innovative therapies for patients.”
“This is an incredibly exciting collaboration with a recognised global leader in the industry. Sirtex will be able to nimbly move the project from development to regulatory approvals and commercialisation, and we look forward to working closely with their team for optimal success,” says Justin Pierce, Magle Chemoswed’s CEO.
“We are thrilled to begin the collaborative programme with Magle Chemoswed to combine our resources and expertise,” says Mark Turco, Global Chief Medical Officer and EVP, Research and Development of Sirtex. “This technology will open the door to new product development opportunities for optimal patient care.”